The need for a national infrastructure to improve the rational use of therapeutics
- 18 April 2002
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 11 (4) , 319-327
- https://doi.org/10.1002/pds.699
Abstract
The current medical care environment has created expectations that exceed its capabilities, one effect of which has been an increasing awareness of lapses in the quality of healthcare, including medical errors. As more new therapies reach clinical application, the expectations on the part of the public are unlikely to lessen, and yet the ability to assure patients that the benefits of these therapies are known, and that they are without serious side‐effects or untoward consequences, eludes the healthcare system. Based on initial experience with a new federal program, the Centers for Education and Research on Therapeutics (CERTs), we propose a national approach to therapeutics education and research, through a public–private partnership that involves academic medical centers, the federal government, industry, and the public. Through a concerted approach, we believe that significant gaps in our understanding of key issues in therapeutics and our ability to educate practitioners, policy makers, and consumers can be significantly enhanced in a manner that could not be achieved without a coordinated approach. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 35 references indexed in Scilit:
- Guided Medication Dosing for Inpatients With Renal InsufficiencyJAMA, 2001
- How Do Observational Studies Expand the Evidence Base for Therapy?Published by American Medical Association (AMA) ,2001
- Physical Examination Skills of US and International Medical GraduatesPublished by American Medical Association (AMA) ,2001
- Educational Program for Physicians to Reduce Use of Non-Steroidal Anti-Inflammatory Drugs Among Community-Dwelling Elderly PersonsMedical Care, 2001
- Risk management of marketed drugs: FDA and the interface with the practice of medicinePharmacoepidemiology and Drug Safety, 2001
- Will Genetics Revolutionize Medicine?New England Journal of Medicine, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Treatment with beta-adrenergic blocking agents after myocardial infarction: From randomized trials to clinical practiceJournal of the American College of Cardiology, 1995
- A Comparison of Outcomes in Men 11 Years after Heart-Valve Replacement with a Mechanical Valve or BioprosthesisNew England Journal of Medicine, 1993